Amitriptyline hydrochloride
PreclinicalSmall molecule
Amitriptyline hydrochloride is one of 61 small molecule programs targeting Peripheral Neuropathy. It is currently in Preclinical.
2
Indications
6
Total Trials
0
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
42 competitors in Fibromyalgia
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Savella
AbbVieApproved
Cymbalta
Jazz PharmaceuticalsApproved
Elavil
AstraZenecaApproved
Keppra
UCBApproved
Emgality
Eli LillyApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Revia
TevaApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Ultram
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Irritable Bowel Syndrome1 trial
To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea
Completed·—·Phase 4·NCT05867550·162 enrolled
Fibromyalgia1 trial
Peripheral Neuropathy1 trial
HIV infection1 trial
A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000793·240 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amitriptyline hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details